CLINICAL_TRIALS
trial_result
· 2017-08-11
Clinical Trial Update: First Time Use of SD-809 in Huntington Disease [Phase 3]
Summary
Phase 3 trial update on the first use of SD-809 (deutetrabenazine) for Huntington disease–related chorea.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chorea | Phase 3 | Status: COMPLETED | Results posted: 2017-08-11